Huaren Biology-B (02396): The stable price period has ended, no stable pricing actions, and the oversubscription rights have expired.

Huarent Bio-B (02396) announced that the stabilization period of the global offering ended on January 16, 2026 (Friday) (30 days after the deadline for submitting the Hong Kong public offering application). There were no additional allocations of shares under the international offering. Therefore, the oversubscription rights were not exercised, and the oversubscription rights expired on January 16, 2026 (Friday). The Company has been informed by the stabilizing manager that the stabilizing manager (or any person acting on its behalf) did not take any stabilization action during the stabilization period.